496 filings
Page 5 of 25
FWP
0zjhn59j oy7
19 Jan 21
Free writing prospectus
5:01pm
424B5
7ri fshdsi2ozplx
19 Jan 21
Prospectus supplement for primary offering
5:00pm
EFFECT
lae339e2pew7n
12 Jan 21
Notice of effectiveness
12:15am
CORRESP
hma29vme04kakrq
11 Jan 21
Correspondence with SEC
12:00am
UPLOAD
czlai hnq6859jmb3043
6 Jan 21
Letter from SEC
12:00am
F-3
ajxzwqb
31 Dec 20
Shelf registration (foreign)
4:37pm
424B5
9zi6fekpbgjgspo
31 Dec 20
Prospectus supplement for primary offering
4:31pm
6-K
mtb0zx28m1
16 Dec 20
Current report (foreign)
8:00am
6-K
whdsz3tp ucnzuguieh
16 Dec 20
BioLineRx Announces Final Results from Phase 2a
6:02am
6-K
c55hy340x8 dw6l7
23 Nov 20
BioLineRx Reports Third Quarter 2020 Financial Results
7:08am
6-K
slwvbpbolbfmgeam1
18 Nov 20
BioLineRx Announces Initiation of Phase 1b Clinical Trial
7:09am
424B5
m820jci p0fgmznds
13 Nov 20
Prospectus supplement for primary offering
4:31pm
6-K
oiaavy xqq8z6hxvuj9m
30 Oct 20
BioLineRx Announces Positive Results from Interim Analysis of
7:09am
6-K
5zp pm41e
29 Oct 20
BioLineRx Announces Initiation of Phase 2 Clinical Trial
8:45am
6-K
c0ioqbe xaf0
25 Sep 20
Current report (foreign)
4:33pm
424B5
eim1ny53vkylqo3
25 Sep 20
Prospectus supplement for primary offering
4:30pm
6-K
1m6ro5qbqeib0
24 Sep 20
Current report (foreign)
4:30pm
6-K
anflf lqbgvoma63qzke
19 Aug 20
2020 Annual General Meeting of Shareholders
4:34pm
6-K
aebzunw1m 9hjaruaw7q
19 Aug 20
BioLineRx Achieves Enrollment Target in Phase 3
7:08am
EFFECT
980ftc5xhpddet8ha7
13 Aug 20
Notice of effectiveness
12:15am